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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory joint 
disease, causing erosion of the joints and ultimately invalidity. RA is 
diagnosed through symptom evaluation of tender joints, swollen joints, 
and synovial hyperplasia with accompanying synovitis. The disease is 
thought to progress through an autoimmune phase, which begins with 
the break of tolerance to self-antigens, i.e. autoantigens. This leads to 
subclinical inflammation, succeeded by clinical inflammation, at which 
point the disease is often diagnosed [1]. Anti-citrullinated protein 
antibodies (ACPAs) are an early characteristic in the development of 
the majority of RA patients (up to 70%), and the presence of ACPAs is 
used to further establish the RA diagnose. Citrullination is a normally 
occurring protein modification of arginine, which in vivo is catalyzed 
by the peptidylarginine deiminase (PAD) family of enzymes [2,3]. 
Clinical diagnosis of RA is often not established until a patient 
has developed advanced autoimmunity. Therefore, the treatment 
with disease-modifying anti-rheumatic drugs (DMARDs) must be 
intensive to avoid further irreversible joint damage. Upon failure 
with conventional DMARDs, biological DMARDs (bDMARDs) are 
used to target specific pro-inflammatory mediators. The bDMARDs 
are humanized antibodies against receptors or polymeric receptor 
pharmaceuticals. The increasing assortment of bDMARDs and number 
of in vivo targets has enabled multiple intervention points in the 
immunological cascade. A relatively new bDMARD, tocilizumab, is a 
humanized recombinant monoclonal antibody against interleukin 6 
receptor (IL-6R) that prevents binding and signal transduction from the 
natural ligand IL-6. Blocking of the IL-6 signaling pathway has a strong 
therapeutic effect in RA patients, without major systemic toxicity [4-6]. 
Elevation in plasma IL-6 levels precedes a rise in C-reactive protein 
(CRP) [7]. CRP is an often used surrogate biomarker for inflammatory 
activity, and has potential for diagnostic use for monitoring early RA 
disease activity [8]. IL-6 stimulates the hepatic release of acute phase 
reactants, which makes the CRP concentration a surrogate marker for 
tocilizumab efficacy [9]. IL-6 signals through the JAK/STAT signaling 
pathway. Interestingly, IL-6R is also found secreted in a soluble form, 
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and is able to exert trans signaling in all glycoprotein (gp)130 expressing 
tissues [10]).  Tocilizumab adequately prevents binding and activation 
of IL-6R throughout a dosing interval, confirmed by sustained high 
levels of tocilizumab-bound IL-6R complexes [11]. The inhibition of 
this signaling pathway is, therefore, thought to dampen further the 
inflammatory response. 
In this proof-of-concept study, we examined the effects of IL-6R 
inhibition treatment on biological molecular pathways in a 59 year 
old female patient diagnosed with RA. The patient had an inadequate 
response to DMARD, and it was decided to initiate treatment with 
tocilizumab. To assess the immunological post-treatment outcome 
we applied quantitative proteome analysis to evaluate changes in the 
proteome profile of different biological pathways in leukocyte cell 
populations, important to RA pathogenesis. The leukocytes were 
isolated by positive enrichment of CD14+, CD4+, CD8+, CD19+, and 
CD56+ cells. Here we report a proteomic research method to measure 
IL-6R inhibition before and after start of treatment in a RA patient. 
Methods
The project was approved by the ethical committee of Northern 
Jutland, Denmark (N-20120074), and the participant had given an 
informed written consent to participate in the study. At the beginning 
of the study, the patient had a high disease activity, a poor response 
to regular DMARD, and was eligible for treatment with bDMARDs in 
accordance with “The Danish Rheumatic Society” guidelines.
Peripheral blood mononuclear cell isolation and separation 
Peripheral blood was collected in a EDTA vacutainer and mixed 
2:1 (20mL + 10mL) with RPMI-1640 (Sigma Aldrich, St. Louis, USA), 
and centrifuged at 800 g for 30 min at 22°C in Accuspin System-
Histopaque-1077 tubes (Sigma-Aldrich, St. Louis, USA). The plasma 
was discarded and the monocyte layer and residual Histopaque-1077 
was diluted to a total volume of 50 mL with RPMI-1640, and 
centrifuged at 800 g for 10 min at 4°C. The supernatant was discarded 
and the PBMCs were resuspended into a total volume of 20 mL 
RPMI-1640, centrifuged at 800 g for 10 min at 4°C. The supernatant 
was discarded, and the PBMCs were resuspended into a total volume 
of 1 mL and centrifuged at 800 g for 10 min at 4°C. The supernatant 
was discarded and the PBMCs were resuspended with 1 mL binding 
buffer (0.1% BSA, 2 mM EDTA in Ca2+ and Mg2+ free PBS) and mixed 
with dynabeads (Thermo Scientific, Waltham, USA), as described by 
the manufacturer. The samples were incubated for 30 min and CD14+, 
CD4+, CD8+, and CD19+ cells were extracted using corresponding 
conjugated dynabeads in subsequent order. CD56+ was extracted using 
CD56 primary antibodies, and Goat-anti-mouse dynabeads Thermo 
Scientific, Waltham, USA), as described by the manufacturer. Separated 
cells were washed twice in Ca2+ and Mg2+ free PBS, and lysed in 350 
µL denaturation and solubilization buffer (5% sodium deoxycholate 
(SDC), 100 mM dithiothreitol, 10 mM tetraethylammonium bromide 
(TEAB)). The total sample extraction, separation, and preservation of 
live cells never exceeded 7 hours. The samples from before treatment 
was stored for 4.5 months at -80°C, and the samples after treatment was 
stored for two weeks at -80°C. Subsequently, all samples were prepared 
for proteome analysis simultaneously, and analysed by LC-MS back-to-
back in a randomized order to reduce experimental bias.
Proteomics – sample preparation
Separated cells were prepared for proteomics analysis using a 
modified filter-aided sample preparation protocol, essentially according 
to Bennike et al. [12], where 100 µg protein, measured on a NanoDrop 
1000 (Thermo Scientific, Wilmington, DE, USA) was extracted from 
the cell lysates, and used for downstream processing. The cell lysates 
were transferred to YM-10kDa spin filter (Millipore) and centrifuged 
at 11.000 g for 15 min at 4°C. The proteins were reduced with 12 
mM Tris (2-Carboxyethyl) phosphine in 5% sodium deoxycholate 
(SDC), 10 mM TEAB for 30 min. at 37°C, and alkylated with 40 mM 
iodoacetamide in 5% SDC, 10 mM TEAB for 20 min at 37°C in the 
dark. Samples were centrifuged at 11.000 g for 15 min at 4°C after each 
step. In preparation for digestion, the buffer was exchanged by addition 
of digestion buffer (0.5% SDC, 50 mM TEAB) and centrifuged for 15 
min at 4°C. A 1:50 (w/w) trypsin to protein ratio was added to the spin-
filter, diluted in 50 µL digestion buffer followed by overnight trypsin 
digestion. The peptides were retrieved with 50 mM TEAB buffer and 
a phase separation was performed in 3:1 (v/v) ethyl acetate:sample 
acidified by addition of formic acid (FA) to a final concentration of 
0.5%. Total phase separation was achieved by 2 min agitation and 
centrifugation at 11.000 g for 2 min at 4°C. The aqueous phase was 
collected and dried in vacuum in preparation for resuspension in LC-
solution (2% acetonitrile (ACN), 0.1% FA).
Proteomics – mass spectrometry analysis
The injected peptide sample amounts per UPLC-MS analysis was 
normalized using absorbance at 280 nm measured on a NanoDrop 
1000 (Thermo Scientific, Wilmington, DE, USA) which was calibrated 
with LC-solution. 5 µg total peptide was analyzed per UPLC-MS run, 
diluted with LC-solution to a total volume of 10 µL, and the samples 
were analyzed in a random order in triplicates. The acquisition of 
MS-data was obtained in one block during approximately one week. 
The triplicates were analyzed consecutively (i.e. not randomized), and 
followed by a quality control with BSA to ensure system performance, 
retention-time stability, and to minimize sample cross contamination 
between different samples.
The samples were analyzed using an UHPLC-nanoESI MS/MS 
setup with a Dionex RSLC nanopump (Dionex/Thermo Scientific, 
Waltham, USA). The system was coupled online with an emitter for 
nanospray ionization picotip 360-20-10 (New objective, Woburn, MA, 
USA) to a Q Exactive Plus mass spectrometer (Thermo Scientific, 
Waltham, USA). The peptide material was loaded onto a C18 reversed 
phase column (Dionex Acclaim PepMap RSLC C18, 2 μm, 100 Å, 75 
μm × 2 cm) and separated using a C18 reversed phase column (Dionex 
Acclaim PepMap RSLC C18, 2 μm, 75 Å, 75 μm × 50 cm) kept at 40°C. 
The sample was eluted with a gradient of 96% solvent A (0.1% FA) and 
4% solvent B (0.1% FA in ACN), which was increased to 8% solvent B 
on a 5 minutes ramp gradient and subsequently to 30% solvent B on a 
225 minutes ramp gradient, at a constant flow rate of 300 nL/min. The 
mass spectrometer was operated in positive mode, selecting up to 12 
precursor ions based on highest intensity for HCD fragmenting.
Proteomics – data analysis
The raw data-files were searched using MaxQuant 1.5.1.2 against 
all reviewed Homo sapiens Uniprot proteins (November, 2014). 
Standard settings were employed with carbamidomethyl (C) as a static 
modification, and protein N-terminal acetylation, deamidation (NQ) 
and citrullination (R), and phosphorylation (STY) were included as 
variable modifications. All proteins and peptides are reported below a 
1% false discovery rate (FDR) cutoff, to ensure only high-confidence 
protein identifications.
The results were processed using Perseus v1.5.0.31. Initially, 
all reverse database hits and proteins tagged as contaminants (i.e. 
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abundant plasma proteins) were removed from further analysis, and 
the data was log2-transformed. Two unique peptides or more were 
required for a protein identification and quantification to ensure 
high-quality quantification. The protein abundances were investigated 
triplicate-wise, by scatterplots of all protein quantifications to evaluate 
reproducibility. For the purpose of conducting principal component 
analysis (PCA), missing values were replaced by imputation with values 
from a normal distribution (width 0.3 and down shift 1.8), calculated 
separately for each cell type to simulate signals from low-abundant 
proteins. For the analysis we compared Day 0 samples vs. Day 4 
months treatment samples [13]. Proteins with a statistically significant 
abundance change prior to and following treatment were identified for 
each cell type using two-sample t-tests. As several thousand t-tests were 
performed, the results were corrected for multiple hypothesis testing 
in Perseus using permutation based FDR with standard parameters 
(FDR=0.05, S0=1 and 250 randomizations) [12,14]. A volcano plot 
was generated with x-axis log2 (mean protein abundance differences), 
and y-axis –log10 (mean difference p-value). Based on the 5% 
permutation-based FDR a significance cutoff was included. A subset 
of the protein associations were analyzed into greater detail based on 
associated KEGG pathways, metabolic and signaling pathways and 
Gene ontology groups (Activation of immune response; Activation of 
innate immune, acute inflammatory response, acute-phase response). 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with 
the dataset identifier PXD002686 [15,16].
Results 
Clinical response to IL-6R inhibition
The patient was a 59 year old woman, diagnosed with RA according 
to American College of Rheumatism (ACR) / European League Against 
Rheumatism (EULAR) criteria, with a high disease activity measured 
DAS28 of 5.0 (reference below 2.4), as seen in Table 1. The patient was 
RF and ACPA positive, non-erosive and antinuclear antibody negative. 
Three different DMARDs (first methotrexate oral, then methotrexate 
subcutaneous then sulfasalazine combined with leflunomide), were 
applied with no improvement, before treatment with tocilizumab 
monotherapy was initiated. In the study period, the patient was 
additionally treated with alendronic acid for osteoporosis and small 
amounts of clobetazol propionate cream for pustulosis palmoplantaris. 
After 4 months of tocilizumab treatment, clinical remission was reached 
and the patient did not develop any side effects. 
Method validation for replica runs and cell isolation 
Five cell populations were isolated before and after four months 
of tocilizumab treatment. Technical triplicates were run on the mass-
spectrometer for each of the 10 isolated cell lines, giving at total of 
30 MS runs. An unsupervised principal component analysis (PCA) 
based on overall proteome data was performed to evaluate replicate 
co-localization, isolation grouping, and treatment response, seen in 
Figure 1. All technical triplicates group together, confirming a high 
repeatability of the applied method. The PCA also provides insight 
into the response of treatment for each cell type. The CD14+ cellular 
proteomes were overall the most changes as indicated by the distance 
on the scores plot of PC1 between the samples ‘’CD14 before’’ versus 
‘’CD14 after treatment’’. Finally, the PCA indicates that each cell type 
can be uniquely identified from its proteome, and that the entire 
proteome changes after four months of treatment, likely as a response.
The CD14, CD4, CD8A, CD19 marker proteins were uniquely 
Parameter Before treatment
After 4 
months
Unit and 
Reference 
value
Date 29-11-2013 12-03-2014 DD-MM-YYYY
Age 59 Years
Disease duration 96 Months
CRP, 8 <2.9 mg/L (<2.9)
Hemoglobin 8,9 8,6 mmol/L (7.3 - 9.5)
Leucocytes 8,5 6,1 x10^9 (3.5 - 10.0)
Neutrophils 5,55 3,05 x10^9/L (2.00 - 7.00)
Lymphocytes 2,13 2,56 x10^9/L (1.30 - 3.350)
Platelets 196 148 x10^9/L, (165-400)
IgM-REF, positive 70 mM/L (<5)
ACPA, positive >600 Unit/L (<10)
ANA negative
Methotrexate 0 0
Leflunomid 0 0
Corticosteroids None None
Prednisolone 0 0 (mg/day)
DAS28-CRP 5.0 2.4
CDAI 31.2 5.3
HAQ score 0.625 1
VAS pain 61 32
VAS fatigue 62 32
VAS Global 67 35
Doctors VAS 45 8
Swollen join count 40 8 0
Tender join count 40 12 1
Table 1: Clinical scores, and biochemistry values at baseline, and after treatment 
with tocilizumab. CRP=C-reactive protein, ACPA=anti citrullinated protein antibody, 
ANA=antinuclear  antibodies, DAS28-CRP=disease activity score based on CRP 
and 28 joint count of swollen/tender joints, CDAI=Clinical Disease Activity Index, 
HAQ=Health Assessment Questionnaire,  VAS=visual analogue scale. 
 
Figure 1: Proteomics data validation. a) Scores plot of all measured label-free 
quantitation values (LFQ) for the repeated analysis of CD14+ cells, Pearson’s 
correlation coefficients (R) are given. b) Principle components analysis scores 
plot with all protein abundances as input. Principle component 1 versus 
principle component 2 are plotted to investigate the variation between the 
leucocyte populations at baseline and after 4 months of treatment. Each set of 
triplicate samples are depicted, and labeled with the appropriate CD14 marker 
and treatment name.
detected in their corresponding cell population based on positive 
enrichment, giving validation to the purification method. In addition 
these proteins were non-significantly different in abundance between 
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immune system activation and acute phase responses are presented in 
Table 3 and the complete list of differentiating proteins for each cell 
type is provided in supplemental tables 1-5.
An interesting discovery was that several Protein S100 family 
known to be involved in regulation of many cellular processes including 
inflammation demonstrated similar abundance changes throughout the 
different cell populations (Tables 1 and Supplemental table 1-5). Protein 
S100-A9 was less abundant during treatment in CD14+, CD8+, CD19+, 
and CD56+ to 9%, 9%, 41%, and 41%, respectively. On the other hand 
Protein S100-A10 was increased in abundance during treatment in 
CD14+, CD8+, and CD56+ cells to 754%, 209%, and 199%, respectively. 
Protein S100-A11 abundance was decreased in CD14+, and CD4+ 
cells to 5%, and 41%, respectively, while Protein S100-A6 abundance 
was decreased to 5% in CD14+ cells. S100-A8 and S100-A9 can bind 
and constitute the calcium-binding protein complex calprotectin. 
Calprotectin is released by neutrophils under inflammatory conditions 
and has the capacity to induce apoptosis in various cells [17]. 
The CD14+ cells before and after treatment were investigated in 
greater detail. The DNA-dependent protein kinase catalytic subunit 
was found with 5,501% abundance (55-fold). This protein has been 
linked to methotrexate treatment in cell culture experiments, which 
this patient did not receive at during the sample period. Additionally, 
tyrosine-protein kinase csk (CSK) (4,831%, 48-fold), tyrosine-
protein kinase lyn (LYN) (4,217%; 42-fold), ferritin family homolog 
3 (FERMT3) (11,457%; 114-fold), and signal transducer and activator 
of transcription 1 (STAT1) (4,924%; 49-fold) were also among the top 
ten proteins measured with the highest overall abundance difference 
before and during treatment. CSK acts upstream from LYN, and 
both are important enzymes in intracellular inflammatory signaling 
pathways, e.g. TLR4, while FERMT3 is an activator of integrins in 
integrin-mediated platelet, and leucocyte adhesion. STAT1 is directly 
downstream from the IL-6R.
Discussion
We have conducted the first in-depth immunoproteome analysis of 
different cell-types prior to and after treatment with tocilizumab, with 
the aim to identify differentiating signaling pathways of each cell type 
as a result of the treatment. Proteins displaying a statistically significant 
change in abundance were identified by two-sample t-tests with 
permutation-based FDR control. A single healthy control was omitted, 
because this experiment is based on paired samples, i.e. before and after 
treatment, which provides a large reduction in noise. Healthy controls 
are biologically very different, and therefore it is necessary to include 
several healthy controls, so that noise can be averaged out. Thus, the 
main result of the study is proteomic response profiles for each cell 
type, as a result of the treatment.
Signaling through the JAK/STAT cascade
We investigated the known signal transduction pathways linked 
to IL-6 stimulation within the five immune cell types in order to 
gain a putative insight into the cytokine/hormone environment that 
the cells interact with. The regulation of the JAK/STAT pathway was 
analyzed in each cell type to investigate the direct response to IL-6R 
inhibition. Overall, the CD14+ cells seemed to be most responsive to 
IL-6R inhibition followed by the CD19 cells, based on the number 
of proteins with differentiating abundances. The need for specifically 
targeting the classical IL-6R versus soluble-IL-6R has recently been 
discussed, because studies have shown that IL-6R expression in CD4+ 
cells recovered from sites of disease (e.g. synovial fluid) lack expression 
before and after, which further validates loading control, and 
normalization.
Proteomics data overview
The isolated leucocyte populations were analyzed in technical 
triplicates resulting in a combined total of 4,341 identified proteins at 1% 
FDR, hereof 3,242 qualifying for label free quantification (supplemental 
tables 1-5; ProteomeXchange). Proteins with a statistically significant 
change in abundance between each leucocyte fraction before and 
during tocilizumab treatment were identified by two-sided independent 
sample t-test, and can be seen in Figure 2. The number of proteins with 
a statistically significant change of abundance versus all proteins was 
distributed as follows: CD4+ cells 136/2,563, CD8+ cells 677/2,267, 
CD19+ cells 479/2,193, and CD56+ cells 245/2,104. Based on the number 
of protein abundance changes, the CD14+, and CD8+ cell types were 
the most responsive to IL-6R inhibition. Based on the result, the CD4+ 
cells and CD56+ cells were the least responsive to IL-6R inhibition on 
the proteome level. We mapped quantified proteins to their respective 
signaling, gene ontology or metabolic pathways, where proteins related 
to glucose, tricarboxylic acid (TCA) cycle, and pentose phosphate is 
given for each of the five cell types in Table 2. For easy comparison, 
we converted the log2 transformed abundance changes to percentage, 
relative to time point Day 0.
Acute phase and Treatment specific protein abundance 
changes
The proteomic data was further investigated with a focus on the 
treatment with IL-6R inhibition by tocilizumab and investigation of 
proteins associated to relevant biological processes if inflammation 
(activation of immune response; activation of innate immune; acute 
inflammatory response; acute-phase response). Proteins with a 
statistically significant abundance change known to be associated to 
 
Figure 2: Each dot represent a quantified protein, and the significantly more 
abundant proteins have been highlighted in red. Positive differences indicates 
that the given protein is more abundant after treatment, and vice versa. The 
number of statistically more and less abundant protiens, as well as non-
statistically significanlty proteins is labelled on the figure. E.g. for CD14+, 327 
proteins were significantly more abundant following 4 months of treatment, 
284 proteins were signifantly less abundant, and 2203 proteins were not 
measured with a significant abundance change.
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Protein name Accessionnumber
Cell type and percentage abundance difference
0 vs 4 months (* Significant)
Glycolysis CD14+ CD4+ CD8+ CD19+ CD56+
Phosphoglucomutase 1 P36871 329.4% * 118.4% 72.3% 156.9% 93.8%
Phosphoglucomutase 2 Q96G03 1796.4% 134.4% 175.5% * 114.9% 103.4%
Glucose-6-phosphate isomerase P06744 864.5% * 91.4% 104.9% 252.6% * 122.2%
Hexokinase 1 P19367-4 1946.9% * 144.3% 132.7% 192.9% * 114.2%
Hexokinase 3 P52790 5310.6% * 57.3%
Phosphofructoknase Type C Q01813 645.7% * 165.4% 113.9% 152.9% 120.3%
Fructose-1,6-bisphosphatase 1 P09467 485.5% * 162.8% 174.8% 20.8% * 21.0% *
Triose phosphate isomerase P60174-1 171.0% 105.5% 146.4% 120.5% 122.9%
Glyceraldehyde 3-phosphate dehydrogenase P04406 89.5% 99.9% 95.4% 112.6% 90.1%
Phosphoglycerate kinase P00558 167.0% 123.0% 132.5% 100.0% 123.7%
Phosphoglycerate mutase P18669 39.9% 119.3% 114.0% 95.7% 105.3%
Enolase P06733 100.2% 93.3% 88.8% 119.3% -0,08
Pyruvate kinase P14618 341.2% * 133.6% 122.7% 144.0% 112.3%
Phosphoenolpyruvate carboxykinase, mitochondrial Q16822 516.1% * 103.8% 472.1% * 22.0% * 119.6%
Alcohol dehydrogenase (class 3) P11766 443,5% * 160.7% 248.1%* 284.7%* 182.4%
alcohol dehydrogenase (NADP+) P14550 726.1% * 148.9% 276.2% * 77.8% 109.5%
L-lactate dehydrogenase A chain P00338 664.4% * 98.8% 93.8% 158.6% 109.0%
L-lactate dehydrogenase B chain P07195  231.0% * 126.1% 57.8% * 176.5% * 136.6%
Pyruvate dehydrogenase P11177-2 915.2% * 185.4% 125.6% 71.5% 106.8%
Aldehyde dehydrogenase, P05091 684.1% *
TCA Cycle
ATP-citrate synthase P53396-2 1451.1% * 116.6% 195.5% * 85.2% 86.7%
Aconitate hydratase Q99798 1343.3% * 113.2% 167,4% * 72.5% 143.5%
Isocitrate dehydrogenase [NADP] cytoplasmic O75874 404.7% * 81.9% 110.8% 114.5% 98.6%
Isocitrate dehydrogenase [NADP], mitochondrial P48735 238.4% * 88.0% 105.8% 160.1% 133.3%
  2-oxoglutarate dehydrogenase F5H801 150.8% 146.3% 163.4% 417.4% * 105.3%
  Dihydrolipoyl dehydrogenase B4DT69 101.0% 86.9% 116.3% 151.7% 112.6%
Succinyl CoA synthetase Q96I99 679.5% * 130.5% 177.7% * 77.0% 122.8%
Succinate deydrogenase D6RFM5 434.8% * 78.8% 211.5% * 171.9% 198.7%
Fumarate hydratase P07954-2 1636.1% * 156.4% 155.8% 81.9% 107.0%
Malate dehydrogenase, cytoplasmic P40925 61.5% 79.8% 145.3% 75.9% 158.1%
Malate hydrogenase, mitochondrial P40926 92.7% 83.4% 254.9% * 162.3% 187.7% *
Pentose Phosphate Pathway
Glucose 6-phosphate dehydrogenase P11413 1289.6% * 84.2% 96.7% 168.6% 187.7%
6-phosphogluconate dehydrogenase B4DQJ8 360.0% * 103.6% 99.1% 130.1% 109.2%
Ribose-5-phosphate isomerase P49247 130.8% -0,28  441.0% * 120.8%
Transketolase P29401 221.9% * 122.0% 136.2% 111.5% 123.6%
Ribulose-phosphate 3-epimerase Q96AT9 44.7% 110.1% 150.7% 125.9% 128.9%
Transaldolase P37837 205.8% 110.5% 216.1% * 147.2% 111.3%
fructose-1,6-bisphosphatase 1 P09467 485.5% * 162.8% 174.8% 20.8% * 21.0%*
6-phosphofructokinase Type C Q01813 645.7% * 165.4% 113.9% 152.9% 120.3%
6-phosphogluconolactonase O95336 205.4% * 116.1% 119.6% 100.8% 118.3%
glucose-6-phosphate isomerase P06744 864.5% * 91.4% 216.1% * 252.6%* 122.2%
Glutathione peroxidase 1 P07203 192.4% * 61.6% 93.1% 100.1% 117.6%
phosphoglucomutase 1 P36871 329.4% * 118.4% 72.3% 156.9% 93.8%
phosphoglucomutase 2 Q96G03 1796.4% 134.4% 175.5% * 114.9% 103.4%
Ribose-phosphate pyrophosphokinase 1 P60891 477,3% 147.9% 387.2%* 117.0% 125.3%
Ribose-phosphate pyrophosphokinase 2 P11908 125.4% 102.8% 64.2%
Table 2: Proteins annotated to the metabolic pathways glucolysis, TCA cycle, and pentose phosphate. Enzyme information from www.uniprot.org, and www.nextprot.org. 
Percentage protein abundance change is given for each cell type. *: Statistically significant change in abundance.
of IL-6R, but are responsive to IL-6 trans-signaling [18,19]. Therefore 
it may not be surprising that the CD4+ T cells were unresponsive to 
tocilizumab treatment, because this drug binds IL-6R and inhibits cell-
expressed IL-6R and soluble IL-6R, thus inhibiting IL-6 trans-signaling.
The JAK/STAT pathways acts by activating the kinases Jak1, Jak2, 
and Tyk2, which in turn phosphorylates STAT1, STAT3, and STAT5 
[20,21]. Treatment of the patient resulted in STAT1 being more abundant 
in CD14+ cells during treatment, and STAT3 being more abundant in in 
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Cell type. and protein name
GOBP
• Activation of immune response
• Activation of innate immune response
• Acute inflammatory response
• Acute-phase response
Accession
number
Percentage 
abundance 
difference:
Day 0 vs. 4 
months
p-value Protein sequence 
length
# peptides % sequence 
coverage
CD4+
Fibronectin P02751-10 604.1% 5.51E-02 2176 28 21.6
Tyrosine-protein kinase BTK Q06187 316.3% 9.51E-03 659 15 34
Stimulator of interferon genes protein Q86WV6 304.7% 1.48E-04 379 7 32.5
Regulator of cell cycle RGCC Q9H4X1-2 263.6% 5.34E-03 117 7 63.2
Nuclear factor NF-kappa-B p100 subunit Q00653-4 248.4% 1.40E-02 899 6 11.2
Ig gamma-1 chain C region P01857 45.0% 4.19E-05 330 11 49.1
Ubiquitin-conjugating enzyme E2 D2 D6RAW0 39.4% 7.86E-03 72 2 40.3
Apoptosis-associated speck-like protein 
containing a CARD
Q9ULZ3 36.8% 1.46E-02 195 13 72.3
CD8+
1-phosphatidylinositol 4.5-bisphosphate 
phosphodiesterase gamma-2
P16885 1837.8% 3.23E-03 1265 21 24
Serine/threonine-protein kinase D2 Q9BZL6 677.2% 2.04E-02 878 6 12.1
Nck-associated protein 1-like P55160-2 495.7% 9.22E-05 1077 10 13
Complement component 1 Q 
subcomponent-binding protein. 
mitochondrial
Q07021 361.5% 2.80E-02 282 7 34.8
Ubiquitin-40S ribosomal protein S27a P62979 358.0% 5.41E-05 156 11 51.9
Tyrosine-protein kinase SYK P43405 351.6% 4.52E-04 635 11 33.2
Tyrosine-protein kinase CSK P41240 305.4% 2.63E-03 450 19 53.6
Fibronectin P02751-10 304.6% 2.47E-03 2176 28 21.6
Phosphatidylinositol 3.4.5-trisphosphate 
5-phosphatase 1
Q92835-2 297.9% 2.48E-03 1188 20 28.5
Gamma-interferon-inducible protein 16 Q16666-3 289.4% 7.34E-05 673 22 42.6
Phosphatidylinositol 4.5-bisphosphate 
3-kinase catalytic subunit delta isoform
O00329 269.0% 6.56E-02 1044 10 13.3
Tyrosine-protein kinase BTK Q06187 260.4% 1.38E-02 659 15 34
Tyrosine-protein phosphatase non-receptor 
type 6
P29350 207.4% 4.49E-05 595 19 41.3
Receptor-type tyrosine-protein phosphatase 
C
P08575-2 188.0% 3.70E-04 1143 48 43.4
Ig kappa chain C region P01834 184.7% 3.87E-04 106 7 90.6
Protein FADD Q13158 46.7% 1.07E-02 208 3 22.1
Lymphocyte cytosolic protein 2 Q13094 42.6% 1.11E-03 533 16 32.1
Complement C3 P01024 41.2% 2.26E-04 1663 17 15
Protein S100-A8 P05109 39.6% 6.97E-03 93 10 51.6
GRB2-related adapter protein 2 O75791 38.0% 9.48E-05 330 12 50
Protein S100-A4 P26447 32.9% 7.58E-06 101 9 49.5
Cytoplasmic protein NCK1 P16333 26.5% 1.14E-02 377 6 24.4
Tyrosine-protein kinase Lck P06239 23.5% 2.50E-02 509 11 30.3
Protein S100-A9 P06702 7.3% 8.90E-05 114 16 98.2
CD14+
Tyrosine-protein phosphatase non-receptor 
type 6
P29350 4976.8% 3.11E-03 595 19 41.3
Tyrosine-protein kinase CSK P41240 4724.3% 2.48E-04 450 19 53.6
Tyrosine-protein kinase Lyn P07948-2 4250.9% 1.85E-04 491 18 42.8
1-phosphatidylinositol 4.5-bisphosphate 
phosphodiesterase gamma-2
P16885 2929.6% 5.69E-03 1265 21 24
Receptor-type tyrosine-protein phosphatase 
C
P08575-2 947.5% 1.25E-04 1143 48 43.4
Cathepsin B P07858 918.2% 7.25E-04 339 6 20.9
Platelet glycoprotein 4 D9IX66 693.6% 2.85E-03 412 8 21.1
Complement component 1 Q 
subcomponent-binding protein. 
mitochondrial
Q07021 385.9% 4.34E-03 282 7 34.8
Cathepsin S P25774 261.0% 2.50E-04 331 6 20.8
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Ubiquitin-conjugating enzyme E2 D2 D6RAW0 221.3% 9.89E-03 72 2 40.3
Stimulator of interferon genes protein Q86WV6 220.0% 4.10E-03 379 7 32.5
Ubiquitin-conjugating enzyme E2 N P61088 195.8% 1.40E-03 152 9 51.3
Apoptosis-associated speck-like protein 
containing a CARD
Q9ULZ3 39.4% 4.22E-02 195 13 72.3
Ig kappa chain C region P01834 39.4% 9.83E-03 106 7 90.6
60 kDa heat shock protein. mitochondrial P10809 35.9% 9.10E-05 573 57 79.4
FYN-binding protein O15117 31.0% 3.98E-03 783 18 35.9
Haptoglobin P00738 25.5% 1.29E-01 406 6 28.1
Lymphocyte cytosolic protein 2 Q13094 15.6% 7.33E-05 533 16 32.1
Vasodilator-stimulated phosphoprotein P50552 14.4% 2.73E-04 380 23 49.2
Wiskott-Aldrich syndrome protein P42768 13.1% 2.34E-04 502 14 43.2
Alpha-1-antitrypsin P01009 12.2% 4.95E-03 418 11 22.5
CCAAT/enhancer-binding protein beta P17676-2 6.3% 1.27E-03 322 2 14.6
CD19+
Fibronectin P02751-10 1638.7% 1.04E-04 2176 NaN 21.6
Integrin beta A8MYE6 1283.8% 3.03E-03 712 NaN 41.9
Phosphatidylinositol 4.5-bisphosphate 
3-kinase catalytic subunit delta isoform
O00329 654.1% 3.22E-04 1044 NaN 13.3
FYN-binding protein O15117 431.6% 1.32E-04 783 NaN 35.9
Signal transducer and activator of 
transcription 3
K7ENL3 407.4% 8.44E-04 722 NaN 24.9
Ribosomal protein S6 kinase alpha-3 P51812 276.8% 9.40E-04 740 NaN 25.8
GRB2-related adapter protein 2 O75791 259.9% 8.57E-05 330 NaN 50
Platelet factor 4 P02776 258.0% 2.13E-03 101 11 42.6
Nck-associated protein 1-like P55160-2 230.3% 8.49E-03 1077 NaN 13
Lymphocyte cytosolic protein 2 Q13094 223.5% 1.25E-02 533 NaN 32.1
Wiskott-Aldrich syndrome protein P42768 209.7% 5.62E-03 502 NaN 43.2
Receptor-type tyrosine-protein phosphatase 
C
P08575-2 195.4% 3.57E-06 1143 NaN 43.4
Ig gamma-1 chain C region P01857 194.5% 6.81E-04 330 11 49.1
Nuclear factor of activated T-cells. 
cytoplasmic 2
Q13469-3 184.2% 4.13E-03 901 NaN 20.9
Regulator of cell cycle RGCC Q9H4X1-2 178.6% 6.55E-02 117 NaN 63.2
Protein canopy homolog 3 Q9BT09 175.2% 9.62E-04 278 10 24.1
Tyrosine-protein phosphatase non-receptor 
type 6
P29350 51.5% 1.38E-03 595 NaN 41.3
Tyrosine-protein kinase SYK P43405 41.1% 1.64E-02 635 NaN 33.2
Mitogen-activated protein kinase 14 Q16539 40.6% 2.38E-03 360 NaN 38.6
Myeloid cell nuclear differentiation antigen P41218 36.5% 1.55E-04 407 NaN 36.1
HLA class II histocompatibility antigen. DP 
beta 1 chain
F5H135 20.6% 8.45E-03 123 NaN 36.6
TNFAIP3-interacting protein 1 E7EMV7 20.5% 3.61E-05 492 NaN 7.7
1-phosphatidylinositol 4.5-bisphosphate 
phosphodiesterase gamma-2
P16885 20.0% 2.82E-04 1265 NaN 24
CD56+
Fibronectin P02751-10 505.6% 1.51E-03 2176 28 21.6
Wiskott-Aldrich syndrome protein P42768 231.6% 2.05E-04 502 14 43.2
Tyrosine-protein kinase ZAP-70 P43403 192.7% 3.39E-02 619 15 32.3
Tyrosine-protein kinase Fyn Q5R3A8 174.5% 5.76E-03 485 7 15.9
Table 3: Proteins annotated to the gene ontology biological processes activation of immune response, activation of innate immune response, acute inflammatory response, 
acute-phase response derived from the annotaion by Peresus. Fold regulation is given for each cell type (in percentage) as well, protein accession number (Uniprot), 
p-value, number of unique peptides and protein sequence coverage.
CD8+ and CD19+ cells during treatment. In addition, STAT6 was more 
abundant in CD19+ cells during treatment. Growth factor receptor-
bound protein 2, which is associated to JAK/STAT signaling, was 
more abundant in CD14+ cells, suggesting an increased activation of 
programmed cell death. Protein phosphatase 1A was more abundant 
in CD14+ cells, which potentially make these cells less responsive to 
anti-inflammatory TGF-β signaling, but also less responsive to pro-
inflammatory TNF-α signaling. Furthermore, phosphatidylinositol 
4,5-bisphosphate 3-kinase was more abundant in CD8+ cells during 
treatment, suggesting more activation of cytokine production, and 
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proliferation. Interestingly, Tyrosine-protein phosphatase non-receptor 
type 6 was more abundant in CD14+ cells during treatment suggesting 
an increased capacity to turn off cytokine signaling.
The JAK-STAT pathway is intimately connected to the MAPK 
signaling pathway, which is responsible for cell proliferation, and 
apoptosis. However, the majority of proteins were not found with 
a statistically significant abundance change. Protein associated to 
the major inflammatory pathway of NF-κB were more abundant in 
CD4+, and CD19+ cells during treatment, indicating an activation of 
the pathway. Protein Kinase A was more abundant in CD4+, CD8+, 
CD19+, and CD56+ during treatment suggesting an upregulation in 
G-protein coupled receptor signaling, which acts upstream from this 
kinase. Interestingly, MAPK signaling in CD19+ cells seemed to be 
affected with several MAPKKKK’s, and MAPKKK’s significantly more 
abundant during treatment, but simultaneously with several MAPK’s 
being less abundant during treatment. It is difficult to deduce the 
tentative consequences of the MAPK signaling changes, but it appears 
that the immune system is being modulated as an effect of the IL-6R 
inhibition.
Metabolism overview - Glycolysis
Glycolysis was especially interesting, because the initial steps in this 
metabolic pathway generates energy anaerobically. Inflammation is an 
energetically expensive process that may deprive the tissues of oxygen. 
Thus, patients with systemic inflammation may experience anemia, 
and resulting fatigue [22]. Inflammation-induced high levels of IL-6 
contribute to anemia through the induction of hepcidin synthesis with 
lowering of transmembrane iron transport, and circulating iron levels 
[23]. Thus supposedly, if oxygen is limited, anaerobic glycolysis may 
be preferable to some extent to generate the energy needed for cell 
homeostasis. Hence, during IL-6R inhibition, increased iron availability 
and thereby erythropoiesis will supply tissues with oxygen and reduce 
the need for anaerobically produced energy through glycolysis. In 
addition to glycolysis, we covered the TCA cycle to follow the flow 
of energy rich molecules, and pentose phosphate to analyze cellular 
protection against inflammatory induced reactive free radical species. 
The key enzymes in these metabolic pathways are tabulated in Table 3 
and further documented in Supplement Table 6.
The CD14+ cells were the most responsive to the treatment as 
determined by the number of proteins with different abundance before 
and during treatment. We therefore focused our data-analysis on these 
cells. Key enzymes within the glycolysis pathway were found with 
increased abundance in the CD14+ in response to IL-6R inhibition. 
Six out of 11 enzymes in glycolysis were statistically more abundant, 
and additional 3 enzymes were less abundant (though not significant). 
In addition, the enzyme phosphoenolpyruvate carboxykinase was 
more abundant in the CD14+ cells, suggesting that more oxaloacetate 
is converted downstream to pyruvate. Within the glycolysis pathway 
hexokinase, and pyruvate kinase are especially important. When the 
amount of metabolites flowing into glycolysis decreases, the amount 
of metabolites flowing out from this process likewise decreases. When 
the energy charge is high, the activity of pyruvate dehydrogenase goes 
down. Interestingly, the abundance of pyruvate dehydrogenase was 
increased in the CD14+, CD8+, CD19+, and CD56+ cells during IL-
6R inhibition. Considering the energy-need, it seems that the higher 
abundance of phosphoenolpyruvate carboxykinase and L-lactate 
dehydrogenase A/B in CD14+ cells, as well as the increased abundance 
of pyruvate dehydrogenase, in CD14+, CD8+, CD19+, and CD56+ cells 
during treatment, suggest an increased enzymatic activity to convert 
lactate in pyruvate, and ethanol into acetate during treatment. Overall, 
it seems that more energy is being produced through glycolysis during 
treatment (which induces disease remission), indicating that the cells 
experience less environmental stress and inflammation.
Metabolism overview - TCA
Downstream from glucose metabolism, several proteins involved 
in the TCA pathway were significantly more abundant in CD14+ 
cells during treatment. Eight out of nine key enzymes were found 
with a differentiating abundance, of which seven were significantly 
different, and one non-significantly. This further establishes, that the 
aerobic energy production of the CD14+ cells has increased as a result 
of the biological treatment. The increase in the abundance of these 
enzymes was less pronounced in the other cells types. Spite most of 
the involved enzymes were non-significantly more abundant across 
the cells types, enzymes with a statistically significant abundance 
increase were identified. For example, citrate synthase was significantly 
more abundant in CD14+, CD8+, and CD19+ cells during treatment, 
suggesting an increased capacity to produce citrate in these cells, and 
thus potential for increased ATP production.
Metabolism overview – pentose phosphate pathway
Reactive oxidative species (ROS) are produced as part of the 
inflammatory response, and confer oxidative stress on the cells, which 
may lead to cell damage and death [24,25]. Thus the metabolic pathways 
associated to this response were analyzed, e.g. the pentose phosphate 
pathway, which protects cells in the body from reactive oxygen species. 
Three of the four enzymes, which generate reducing power through 
the generation two NADPH molecules, were more abundant in the 
CD14+ cells during treatment. The increased reducing power is likely 
connected to the increased oxidative protection against reactive 
oxidative bi-products that necessitates reducing power. Concurrently, 
the various enzymes responsible for interconversion of sugars were 
more abundant during treatment, e.g. transketolase, and transaldolase, 
indicating an increased flow of metabolites back into glycolysis.
Furthermore, Glutathione peroxidase 1, which is a scavenger of 
ROS was more abundant in the CD14+ cells during treatment, further 
indicating an increased protection from radical scavengers. On the 
other hand superoxide dismutase, and catalase were both significantly 
less abundant during treatment, which could be a sign of increased 
aerobic metabolism, and at least an indication that sufficiently large 
numbers of radical scavengers are present.
Glucose-6-phosphate dehydrogenase is also responsible for the 
production of NADPH, which is used by Glutathione peroxidase 1 to 
reduce free radicals. Indeed this protein was also significantly more 
abundant during treatment in CD14+ cells, which suggest a regulation 
in oxidative stress.
Protein S100-family regulation
The Protein S100-family is important in immune regulation, and 
has overlapping importance in inflammatory bowel diseases [12]. It has 
previously been shown that responders to methotrexate have higher 
level of S100-A9 measured in PBMC’s, and non-responders have less 
expression. Our study suggests that S100-A9 might also be applicable as 
a marker for response to IL-6R inhibitors. The presented approach has 
shown that it is possible to locate the specific immune cells responsible 
for S100-A9 being less abundant during treatment, and further studies 
will show if this is consistent in larger groups of patients.
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Overall, treatment with tocilizumab causes changes in the JAK/
STAT and MAPK signaling pathways, increased the glucose metabolism, 
reduced cellular stress responses, and further insight into the regulation 
of important biomarkers in this case study.
Conclusion
In this study we evaluated different signaling- and metabolic 
pathways in a female RA patient prior to and during IL-6R inhibition 
treatment with tocilizumab. The patient was found to have good 
clinical response to the therapy. We investigated proteome changes 
in the leucocyte cell populations of CD14+, CD4+, CD8+, CD19+, and 
CD56+ cells. Overall, the CD14+ cells were the most responsive to the 
treatment based on number of proteins found with a differentiating 
abundance. Tocilizumab treatment resulted in changes in the JAK/
STAT and modulation of the MAPK signaling pathways, increased the 
glucose metabolism, and reduced stress responses. The patient has been 
classified as a good responder to tocilizumab and the entire dataset has 
been compiled into our growing spectral library of patient responses. 
We are expanding the database with the aim to stratify responders and 
non-responders based on the blood samples.
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